VIRGINIA RETIREMENT SYSTEMS ET Al Buys 96,200 Shares of AbbVie Inc. $ABBV

VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in AbbVie Inc. (NYSE:ABBV) by 48.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 293,111 shares of the company’s stock after buying an additional 96,200 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in AbbVie were worth $67,867,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ABBV. Vanguard Group Inc. raised its stake in AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after acquiring an additional 3,380,842 shares during the period. Geode Capital Management LLC boosted its position in shares of AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares in the last quarter. Norges Bank purchased a new stake in shares of AbbVie in the second quarter worth $4,288,200,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of AbbVie by 5.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 12,771,854 shares of the company’s stock valued at $2,675,959,000 after purchasing an additional 713,148 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $229.63 on Wednesday. The company has a market cap of $405.84 billion, a price-to-earnings ratio of 173.96, a PEG ratio of 1.31 and a beta of 0.36. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock’s 50 day simple moving average is $226.67 and its two-hundred day simple moving average is $213.27. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the business posted $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 496.97%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ABBV. Guggenheim upped their target price on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Evercore ISI boosted their price objective on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Scotiabank assumed coverage on AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. Finally, Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.